Drug Interactions between Gaviscon Extra Relief Formula and lansoprazole
This report displays the potential drug interactions for the following 2 drugs:
- Gaviscon Extra Relief Formula (alginic acid/aluminum hydroxide/magnesium carbonate)
- lansoprazole
Interactions between your drugs
No interactions were found between Gaviscon Extra Relief Formula and lansoprazole. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Gaviscon Extra Relief Formula
A total of 257 drugs are known to interact with Gaviscon Extra Relief Formula.
- Gaviscon extra relief formula is in the drug class antacids.
- Gaviscon extra relief formula is used to treat the following conditions:
lansoprazole
A total of 205 drugs are known to interact with lansoprazole.
- Lansoprazole is in the drug class proton pump inhibitors.
-
Lansoprazole is used to treat the following conditions:
- Aspiration Pneumonia (off-label)
- Barrett's Esophagus
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Erosive Esophagitis
- Gastritis/Duodenitis
- GERD
- Helicobacter Pylori Infection
- Hiatal Hernia
- Laryngopharyngeal Reflux (off-label)
- Multiple Endocrine Adenomas
- NSAID-Induced Gastric Ulcer
- NSAID-Induced Ulcer Prophylaxis
- Stomach Ulcer
- Systemic Mastocytosis
- Zollinger-Ellison Syndrome
Drug and food interactions
aluminum hydroxide food
Applies to: Gaviscon Extra Relief Formula (alginic acid / aluminum hydroxide / magnesium carbonate)
GENERALLY AVOID: The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum concentrations, resulting in toxicity. Citrates or citric acid are contained in numerous soft drinks, citrus fruits, juices, and effervescent and dispersible drug formulations. Citrates enhance the gastrointestinal absorption of aluminum by an unknown mechanism, which may involve the formation of a soluble aluminum-citrate complex. Various studies have reported that citrate increases aluminum absorption by 4.6- to 50-fold in healthy subjects. Patients with renal insufficiency are particularly at risk of developing hyperaluminemia and encephalopathy. Fatalities have been reported. Patients with renal failure or on hemodialysis may also be at risk from soft drinks and effervescent and dispersible drug formulations that contain citrates or citric acid. It is unknown what effect citrus fruits or juices would have on aluminum absorption in healthy patients.
MANAGEMENT: The concomitant use of aluminum- and citrate-containing products and foods should be avoided by renally impaired patients. Hemodialysis patients should especially be cautioned about effervescent and dispersible over-the-counter remedies and soft drinks. Some experts also recommend that healthy patients should separate doses of aluminum-containing antacids and citrates by 2 to 3 hours.
ADJUST DOSING INTERVAL: The administration of aluminum-containing antacids with enteral nutrition may result in precipitation, formation of bezoars, and obstruction of feeding tubes. The proposed mechanism is the formation of an insoluble complex between the aluminum and the protein in the enteral feeding. Several cases of esophageal plugs and nasogastric tube obstructions have been reported in patients receiving high-protein liquids and an aluminum hydroxide-magnesium hydroxide antacid or an aluminum hydroxide antacid.
MANAGEMENT: Some experts recommend that antacids should not be mixed with or given after high protein formulations, that the antacid dose should be separated from the feeding by as much as possible, and that the tube should be thoroughly flushed before administration.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.